Engineered & bioprinted tissuereported
VivoSim Labs (formerly Organovo)
Repositioned in Apr 2025 to sell liver and intestinal toxicology services on donor-derived 3D tissue models.
Notable
Company-reported liver model results of 87.5% sensitivity and 100% specificity on a challenge set (May 2025, not peer reviewed).
Related deals
No tracked deals yet.
Related updates
- Apr 24, 2025Organovo relaunches as VivoSim Labs for NAM toxicologybiospace.com(opens in new tab)